Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
30. Januar 2018 08:30 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the launch of Cystinosis United, an initiative created for people living with nephropathic...
Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis
27. Dezember 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved an expansion to the indication for...
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
04. November 2017 11:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
07. September 2016 03:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress
24. August 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical Voted A “Best Places to Work” Company in the North San Francisco Bay Area
18. August 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 11th Annual North Bay...
Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
04. August 2016 16:05 ET
|
Raptor Pharmaceutical Inc
Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million Raptor Raises 2016 Global Net Revenue Guidance to $125-$135 Million Company to Host Conference Call and Webcast Today at...
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
28. Juli 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4,...
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
14. Juni 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:Julie Anne Smith, President...
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR™ at the 39th European Cystic Fibrosis Conference
10. Juni 2016 08:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...